The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Dec. 24, 2024
Filed:
Aug. 05, 2019
Merck Sharp & Dohme Llc, Rahway, NJ (US);
Msd International Gmbh, Lucerne, CH;
Michelle Machacek, Belmont, MA (US);
David Witter, Norfolk, MA (US);
Craig Gibeau, Northborough, MA (US);
Chunhui Huang, Arlington, MA (US);
Shuhei Kawamura, Cambridge, MA (US);
David L. Sloman, Brookline, MA (US);
Phieng Siliphaivanh, Newton, MA (US);
Ryan Quiroz, Boston, MA (US);
Murray Wan, Watertown, MA (US);
Sebastian Schneider, Boston, MA (US);
Charles S. Yeung, Dedham, MA (US);
Michael H. Reutershan, Brighton, MA (US);
Timothy J. Henderson, Beaulieu, MA (US);
Jean-Laurent Paparin, Vendemian, FR;
Houcine Rahali, Beaulieu, FR;
Jonathan M. E. Hughes, Hoboken, NJ (US);
Sulagna Sanyal, Belmont, MA (US);
Yingchun Ye, Belmont, MA (US);
David A. Candito, Wrentham, MA (US);
Patrick S. Fier, Monroe Township, NJ (US);
Steven M. Silverman, Jersey City, NJ (US);
Merck Sharp & Dohme LLC, Rahway, NJ (US);
MSD International GmbH, Lucerne, CH;
Abstract
The present invention provides a compound of Formula (I) and the pharmaceutically acceptable salts, esters, and prodrugs thereof, which are PRMT5 inhibitors. Also provided are methods of making compounds of Formula I, pharmaceutical compositions comprising compounds of Formula I, and methods of using these compounds to treat cancer, sickle cell, and hereditary persistence of foetal hemoglobin (HPFH) mutations.